2 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 5 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow Myeloid Leukemia: new trials by email Literature Review of Myeloid Leukemia trials Research Report on Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Donor lymphocyte preparation depleted of host functional alloreactive T-cells - Myeloid Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Kiadis Pharma | 40 | 2009-08-01 | 2021-06-14 |
| Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) 5-Azacytidin - Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Completed | Technische Universität Dresden | 10 | 2007-01-01 | 2011-07-11 |
| A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups Prophylactic platelet transfusion, Therapeutic platelet transfusion - Myeloid Leukemia | Phase 3 | Completed | Technische Universität Dresden | 400 | 2004-09-01 | 2011-05-19 |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Anthracyclines, liposomal daunorubicin, 2-CDA - Myeloid Leukemia | Phase 2 / Phase 3 | Unknown | University Hospital Muenster | 550 | 2004-03-01 | 2012-05-23 |
Leukemia, Myeloid (5) · Leukemia, Myeloid, Acute (3) · Leukemia (2) · Myelodysplastic Syndromes (2) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Leukemia (3) · Bone Marrow Diseases (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1)
Anthracyclines (1) · Cladribine (1) · Cyclophosphamide (1) · Daunorubicin (1) · Idarubicin (1) · Whole-Body Irradiation (1) · fludarabine (1)
Technische Universität Dresden (2) · Actinium Pharmaceuticals (1) · Kiadis Pharma (1) · University Hospital Muenster (1)
Germany (4) · Belgium (1) · Canada (1) · Italy (1) · Netherlands (1) · United Kingdom (1) · United States (1)
Andrea Velardi, MD (1) · Denis-Claude Roy, MD (1) · Dirk Reinhardt, Prof. Dr. med. (1) · Gerhard Ehninger, Prof. (1) · Katy Rezvani, MD PhD (1) · Stephan Mielke, MD (1) · Ursula Creutzig, Prof. Dr. med. (1) · Uwe Platzbecker, MD (1)
PMID 18083847, PMID 18182574, PMID 21480469, PMID 22877506, PMID 23704089, PMID 26202768, PMID 26814618, PMID 27269945, PMID 40803346